Development of testing systems for cancer treatment selection and assessment of treatment efficacy

「In September and November 2024, the company obtained marketing approval for the “Genetic Analysis Program MINtS Analyzer” and the “MINtS Lung Cancer Multi CDx Library Preparation Reagent Kit,” respectively, and the products became eligible for reimbursement in December of the same year.」

「To contribute to personalized medicine, we applied for regulatory approval of “Mutation Investigator using the Next-era Sequencer,” a testing system covering the selection of therapeutic drugs and assessment of treatment efficacy, which detects and analyzes multiple genetic abnormalities in lung cancer simultaneously using a next-generation sequencer (hereinafter, “MINtS”). In addition, we registered part of our Nogi facility as a medical laboratory (name: “Eiken Chemical Clinical Laboratory”) and launched a contract testing business using MINtS.」

「To address these medical challenges in addition to cancer prevention and early detection, we aim to further reduce cancer mortality by developing and providing testing systems covering the selection of therapeutic drugs and assessment of treatment efficacy.」